AR069188A1 - Compociones y metodos para tratar una hemorragia uterina disfuncional - Google Patents

Compociones y metodos para tratar una hemorragia uterina disfuncional

Info

Publication number
AR069188A1
AR069188A1 ARP080104830A ARP080104830A AR069188A1 AR 069188 A1 AR069188 A1 AR 069188A1 AR P080104830 A ARP080104830 A AR P080104830A AR P080104830 A ARP080104830 A AR P080104830A AR 069188 A1 AR069188 A1 AR 069188A1
Authority
AR
Argentina
Prior art keywords
methods
dysfunctional uterine
uterine hemorrhage
patient
compound
Prior art date
Application number
ARP080104830A
Other languages
English (en)
Inventor
Ronald D Wiehle
As Andre Van
Joseph S Podolski
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of AR069188A1 publication Critical patent/AR069188A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

El objeto de la presente está dirigido al campo de la terapia hormonal, se refiere a métodos de tratamiento de una hemorragia uterina disfuncional, el tratamiento y/o la prevencion de anemia en pacientes con hemorragia uterina disfuncional. Composiciones para la práctica de los métodos que comprenden antagonistas de progesterona, métodos para identificar nuevos moduladores selectivos del receptor de progesterona para la práctica de los métodos de tratamiento revelados. Reivindicacion 1: Un método de tratamiento de hemorragia uterina disfuncional en una paciente, caracterizado porque comprende administrarle a dicha paciente una cantidad eficaz de una composicion que comprende un compuesto de la formula (1), o una sal aceptable para uso farmacéutico, hidrato o solvato del mismo, en donde: X representa un alquilo, alquenilo, alquinilo, hidrogeno, halo, monoalquilamino o dialquilamino; R1 representa O, NOH o NO-metilo; R2 representa un hidrogeno o acetilo; y R3 representa metiloxi, formiloxi, acetoxi, acetilteonilo, glicimato, viniléter, acetiloximetilo, carbonato de metilo, halogenos, metilo, hidroxi o etiloxi, en donde la cantidad de dicha composicion es eficaz para tratar una hemorragia uterina disfuncional en dicha paciente. Reivindicacion 2: El método de la cláusula 1, caracterizado porque dicho compuesto es CDB-4124. Reivindicacion 11: El método de la reivindicacion 10, caracterizado porque dicho compuesto es administrado por un período de al menos entre aproximadamente uno y aproximadamente seis meses.
ARP080104830A 2007-11-05 2008-11-04 Compociones y metodos para tratar una hemorragia uterina disfuncional AR069188A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98552807P 2007-11-05 2007-11-05

Publications (1)

Publication Number Publication Date
AR069188A1 true AR069188A1 (es) 2010-01-06

Family

ID=40091934

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104830A AR069188A1 (es) 2007-11-05 2008-11-04 Compociones y metodos para tratar una hemorragia uterina disfuncional

Country Status (5)

Country Link
US (1) US20090118253A1 (es)
AR (1) AR069188A1 (es)
CL (1) CL2008003070A1 (es)
TW (1) TW200927137A (es)
WO (1) WO2009061569A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714959B2 (en) * 1995-02-02 2000-01-13 Schering Aktiengesellschaft Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding
DK0900234T3 (da) * 1996-05-01 2000-11-06 Us Gov Health & Human Serv 21-substituerede progesteronderivater anvendt som nye antigestagener
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
IN191020B (es) * 2000-03-28 2003-09-13 Dabur Res Foundation
ATE461681T1 (de) * 2003-04-29 2010-04-15 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
PT2148681E (pt) * 2007-04-20 2016-06-17 Preglem Sa Moduladores seletivos da progesterona no tratamento da hemorragia uterina

Also Published As

Publication number Publication date
US20090118253A1 (en) 2009-05-07
WO2009061569A1 (en) 2009-05-14
TW200927137A (en) 2009-07-01
CL2008003070A1 (es) 2009-03-27

Similar Documents

Publication Publication Date Title
AR071516A1 (es) Regimenes de dosificacion con antiprogestinas que comprende la administracion de un antagonista de progesterona como el compuesto cdb-4124
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112014016085A8 (pt) composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
SV2010003491A (es) 2- anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015020600A2 (pt) composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição
BR112014010228A2 (pt) inibidores de reciclagem de ácidos biliares para tratamento da doença de fígado e hipercolemia colestática
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
BR112018067906A2 (pt) métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
ATE537833T1 (de) Behandlung des mekoniumaspirationssyndroms mit östrogenen
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
BR112014010223B8 (pt) uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
BR112018015718A2 (pt) utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
CL2007000345A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes.
BR112015013136A2 (pt) dispositivos de filtração posicionáveis in vivo e métodos relacionados aos mesmos
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
BRPI0912112B8 (pt) composição farmacêutica compreendendo composto tendo atividade antagonística em receptor de adenosina a2a útil em suprimir tolerância analgésica
MX369117B (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
BRPI0916282B8 (pt) uso de um agonista do receptor-pgi2 no tratamento de insuficiência renal crônica
AR053928A1 (es) Metodos reactivos para el tratamiento de trastornos inflamatorios
BR112015019776A2 (pt) comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos

Legal Events

Date Code Title Description
FB Suspension of granting procedure